In this presentation, Dr. Richard Manch, MD, provides a comprehensive overview and update as it relates to Steatotic Liver Disease (SLD) and particularly, Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).… […]
Keyword: hepatitis
A National Initiative to Eliminate HCV in the United States | March 20, 2024
In this presentation Dr. Karla Thornton provides an update on the national initiative to eliminate HCV in the United States, including a background on the epidemiology of the the public… […]
Read More… from A National Initiative to Eliminate HCV in the United States | March 20, 2024
Medications for HCV in Pediatric Patients | March 6, 2024
In this presentation, Dr. Paulina Deming discusses the latest guidance on HCV screening in pediatrics, as well recommendations for monitoring and management. Then, Dr. Deming discusses the available HCV medications… […]
Read More… from Medications for HCV in Pediatric Patients | March 6, 2024
Long-Term Follow-Up After HCV Treatment | February 21, 2024
In this presentation, Dr. Paulina Deming discusses the needed follow-up for patients with and without cirrhosis who have completed HCV treatment. […]
Read More… from Long-Term Follow-Up After HCV Treatment | February 21, 2024
HCV Screening, Management and Treatment Guidelines | March 13, 2024
In this training, Dr. Paulina Deming, Dr. Karla Thornton, and Dr. Richard Manch discuss treatment and management of patients with hepatitis C in primary care, including medications, approaches to treatment,… […]
Read More… from HCV Screening, Management and Treatment Guidelines | March 13, 2024
Updates in CDC HCV Testing Recommendations | November 15, 2023
In this presentation, Dr. Paulina Deming describes the risk of HCV infection in perinatally exposed children and identifies when children with perinatal exposure should be tested for HCV. […]
Read More… from Updates in CDC HCV Testing Recommendations | November 15, 2023
Common HCV DAA Drug Interactions | September 27, 2023
In this presentation, Dr. Paulina Deming describes the interaction potential between DAA therapies and common medications, and identifies when DAA therapies and diabetic medications are most likely to result in… […]
Read More… from Common HCV DAA Drug Interactions | September 27, 2023
HCV Treatment Monitoring: Keeping it Simple | August 23, 2023
In this session, Dr. Paulina Deming discusses baseline laboratories recommended for HCV treatment evaluation, identifies patients eligible for simplified monitoring and shares HCV treatment monitoring recommendations. […]
Read More… from HCV Treatment Monitoring: Keeping it Simple | August 23, 2023
HCV Management and Treatment Guidelines | December 5, 2023
In this training, Dr. Jorge Mera discusses treatment and management of patients with hepatitis C in primary care, including medications, approaches to treatment, medication interactions, and treatment monitoring. […]
Read More… from HCV Management and Treatment Guidelines | December 5, 2023
HCV Screening, Management and Treatment Guidelines | October 6, 2023
In this training, Dr. Jorge Mera discusses treatment and management of patients with hepatitis C in primary care, including medications, approaches to treatment, medication interactions, and treatment monitoring. […]
Read More… from HCV Screening, Management and Treatment Guidelines | October 6, 2023